Preferred Label : Povetacicept;
NCIt synonyms : TACI vTD-Fc;
NCIt definition : An affinity-optimized Fc fusion protein composed of an engineered variant domain of
human tumor necrosis factor receptor superfamily member 13B (TNFRSF13B; TNF receptor
superfamily 13B; transmembrane activator and CAML interactor; transmembrane activator
and calcium modulator and cyclophilin ligand interactor; TACI) fused to a human immunoglobulin
(Ig) fragment crystallizable (Fc) domain, with potential immunomodulating activity.
Upon administration, povetacicept targets, binds to and inhibits both a proliferation-inducing
ligand (tumor necrosis factor ligand superfamily member 13; TNFSF13; APRIL; TNF superfamily
13) and B-cell activating factor (tumor necrosis factor ligand superfamily member
13B; TNFSF13B; BAFF; BlyS; TNF superfamily 13B). This inhibits their interaction with
their cell membrane receptors, including TACI, B-cell maturation antigen (tumor necrosis
factor receptor superfamily member 17; TNF receptor superfamily 17; TNFRSF17; BCMA)
and B cell-expressed BAFF receptor (tumor necrosis factor receptor superfamily member
13C; TNFRSF13C; BAFF-R). This inhibits B-cell proliferation and maturation, immunoglobulin
(Ig) secretion, and survival. By inhibiting the production of autoantibodies, povetacicept
inhibits B-cell mediated autoimmune responses. Dysregulated APRIL/ and BAFF signaling
is implicated in the pathogenesis of multiple autoimmune diseases.;
UNII : EN2U82XV65;
CAS number : 2490217-42-8;
Molecule name : ALPN 303; ALPN-303;
NCI Metathesaurus CUI : CL1798875;
Origin ID : C190436;
UMLS CUI : C5783705;
Semantic type(s)
- concept_is_in_subset
